Discover investment opportunities in Stocks Under 10 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 10 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 10 Cents using our Smart AI Filter.
6 stocks found for "Stocks Under 10 Cents"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.79 | ±83.9% | -4.3 | 0.68% | |||
0.82 | ±100.0% | -0.3 | 0.00% | |||
0.59 | ±52.3% | 2.7 | 68317.68% | |||
1.11 | ±75.1% | -18.3 | 0.00% | |||
1.46 | ±68.0% | -1.9 | 0.00% | |||
0.86 | ±55.0% | 41.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the potential rewards of investing in NCNA?
A: NuCana plc (NCNA) is a biopharmaceutical company focusing on cancer treatments. Some investors see potential in NCNA's novel approach to chemotherapy, which aims to improve efficacy and reduce side effects. However, success depends on clinical trial outcomes and regulatory approval.
Q: Why might PTN be considered for growth opportunities?
A: Palatin Technologies, Inc. (PTN) develops targeted receptor-specific therapeutics. Investors interested in biotech may consider PTN due to its proprietary technology platforms and partnership potential. Long-term growth hinges on clinical success and commercial viability.
Q: How does VINC fit into the tech sector?
A: Eyecity Technology Co Ltd (VINC) is associated with the tech sector, but specific details about its operations and market focus are sparse. Those interested should research its latest financial disclosures and strategic moves within the technology landscape.
Q: What unique risk does investing in TTOO present?
A: T2 Biosystems, Inc. (TTOO) develops diagnostic products for critical illnesses. It faces risks common in the medtech industry, including regulatory hurdles and market adoption challenges. Financial stability is a concern given past operational losses.
Q: Is VIRX positioned for growth despite market volatility?
A: Viracta Therapeutics, Inc. (VIRX) is focused on oncology and virus-associated cancers. Growth prospects depend on clinical developments and approvals. Market volatility is a factor, with biotechnology stocks often experiencing significant price fluctuations.
Q: What could drive long-term value in VRPX investments?
A: Virpax Pharmaceuticals, Inc. (VRPX) works on pain management and neurology products. Long-term value may arise from successful product development and regulatory approval. Investors seek evidence of pipeline progress and potential market size.